Drugs / Insulin faster aspart
last change Mar 2024 re-read 2 minutes ago

Insulin faster aspart

also known as Fiasp
Developed for
type 1 diabetes mellitus
Investigated by
Medical University of Warsaw

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04772729 Mar 2021 → Mar 2023 type 1 diabetes mellitus Medical University of Warsaw Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Insulin faster aspart ClinicalTrials.gov intervention name — accepted as the source's own label NCT04772729
Known as Fiasp “Insulin faster aspart (Fiasp, Novo Nordisk)” NCT04772729
Route Subcutaneous “continuous subcutaneous insulin infusion of insulin faster aspart” NCT04772729